To investigate the functional role of RPL35A in lung cancer progression, we first established stable knockdown models in A549 and NCI-H1299 cell lines using two specific shRNA sequences targeting RPL35A. The efficiency of knockdown was successfully validated at both the mRNA and protein levels by quantitative PCR (qPCR) and Western blot (WB) analysis (Fig. S1, A and B). The gene discussed is RPL35A; the disease is lung carcinoma.